Mark Strobeck, Ph.D. is President and Chief Executive Officer at Rockwell Medical. Dr. Strobeck has held leadership positions in both emerging biotechnology and pharmaceutical companies for more than twenty years.
Most recently, he served as Managing Director of Aquilo Partners, LP, a life sciences investment bank. He previously served as Executive Vice President and Chief Operating Officer of Assertio Holdings, Inc., a pharmaceutical company. Prior to that, Dr. Strobeck was Executive Vice President and Chief Operating Officer of Zyla Life Sciences, a pharmaceutical company, from September 2015 through its merger with Assertio Holdings, Inc. in May 2020, and previously served as Zyla’s Chief Business Officer. He served as President and Chief Executive Officer and a director of Corridor Pharmaceuticals, Inc., a pharmaceuticals company, which was acquired by AstraZeneca plc in 2014. Dr. Strobeck served as Chief Business Officer of Topaz Pharmaceuticals Inc., a specialty pharmaceutical company acquired by Sanofi Pasteur in the fourth quarter of 2011. From January 2008 to May 2010, Dr. Strobeck served as Chief Business Officer of Trevena, Inc.. Prior to joining Trevena, Dr. Strobeck held management roles at GlaxoSmithKline plc, a pharmaceuticals company, and venture capital firms SR One Limited and EuclidSR Partners, L.P.
Dr. Strobeck has served on the Board of Directors of Windtree Therapeutics, Inc. (Nasdaq:WINT), a biotechnology company focused on developing novel therapies for respiratory diseases, since June 2023. In addition, he currently serves on the board of directors of Horse Power For Life, a nonprofit organization dedicated to improving the quality of life for individuals diagnosed with cancer, a position he has held since 2012. Dr. Strobeck received his B.S. in Biology from St. Lawrence University and his Ph.D. in Pharmacology and Biophysics from the University of Cincinnati and completed his post-doctoral fellowship at the University of Pennsylvania.
What is Mark Strobeck's net worth?
The estimated net worth of Mark Strobeck is at least $291.48 thousand as of July 1st, 2025. Dr. Strobeck owns 33,775 shares of Rockwell Medical stock worth more than $291,478 as of September 29th. This net worth estimate does not reflect any other investments that Dr. Strobeck may own. Learn More about Mark Strobeck's net worth.
How do I contact Mark Strobeck?
Has Mark Strobeck been buying or selling shares of Rockwell Medical?
Mark Strobeck has not been actively trading shares of Rockwell Medical during the last ninety days. Most recently, Mark Strobeck sold 692 shares of the business's stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $8.20, for a transaction totalling $5,674.40. Following the completion of the sale, the chief executive officer now directly owns 33,775 shares of the company's stock, valued at $276,955. Learn More on Mark Strobeck's trading history.
Who are Rockwell Medical's active insiders?
Are insiders buying or selling shares of Rockwell Medical?
During the last year, insiders at the sold shares 2 times. They sold a total of 793 shares worth more than $7,814.30. The most recent insider tranaction occured on November, 18th when Director
John G Cooper sold 507 shares worth more than $4,410.90. Insiders at Rockwell Medical own 4.6% of the company.
Learn More about insider trades at Rockwell Medical. Information on this page was last updated on 11/18/2025.
